VRTX : Vertex Pharmaceuticals Incorporated stock forecast, predictions, and share price target 2025 - 2026 - 2030 - 2035 with analysis
| year | Average | Low | High | Change from close on 2025-06-17 |
|---|---|---|---|---|
| 2025 | $457.65 | $448.98 | $464.52 | 3.54% |
| 2026 | $372.33 | $280.95 | $440.59 | -15.76% |
| 2027 | $201.04 | $158.41 | $260.68 | -54.51% |
| 2028 | $165.56 | $153.59 | $176.67 | -62.54% |
| 2029 | $136.54 | $96.29 | $170.53 | -69.11% |
| 2030 | $84.52 | $81.04 | $90.91 | -80.88% |
| 2031 | $86.55 | $79.84 | $89.69 | -80.42% |
| 2032 | $73.48 | $71.5 | $78.04 | -83.37% |
| 2033 | $70.93 | $67.26 | $74.48 | -83.95% |
| 2034 | $67.3 | $65.6 | $68.32 | -84.77% |
| 2035 | $66.01 | $65.57 | $66.36 | -85.06% |
The 38 Wall Street analysts offering Vertex Pharmaceuticals Incorporated stock forecast in the last 6 months have average price target of
$484.95 with a high forecast of $583.0 and a low forecast of $407.0.
The average Vertex Pharmaceuticals Incorporated stock forecast represents a 9.72%
increase from the last price of $441.989990234375.
For Vertex Pharmaceuticals Incorporated stock forecast for 2025, 6 predictions are offered for each month of 2025 with average Vertex Pharmaceuticals Incorporated stock
forecast of $457.65, a high forecast of $464.52, and a low forecast of $448.98.
The average Vertex Pharmaceuticals Incorporated stock forecast 2025 represents a 3.54%
increase from the last price of $441.989990234375.
For Vertex Pharmaceuticals Incorporated stock forecast for 2026, 12 predictions are offered for each month of 2026 with average Vertex Pharmaceuticals Incorporated stock
forecast of $372.33, a high forecast of $440.59, and a low forecast of $280.95.
The average Vertex Pharmaceuticals Incorporated stock forecast 2026 represents a -15.76%
decrease from the last price of $441.989990234375.
For Vertex Pharmaceuticals Incorporated stock forecast for 2028, 12 predictions are offered for each month of 2028 with average Vertex Pharmaceuticals Incorporated stock
forecast of $165.56, a high forecast of $176.67, and a low forecast of $153.59.
The average Vertex Pharmaceuticals Incorporated stock forecast 2028 represents a -62.54%
decrease from the last price of $441.989990234375.
For Vertex Pharmaceuticals Incorporated stock forecast for 2030 (5 year), 12 predictions are offered for each month of 2030 with average Vertex Pharmaceuticals Incorporated stock
forecast of $84.52, a high forecast of $90.91, and a low forecast of $81.04.
The average Vertex Pharmaceuticals Incorporated stock forecast 2030 represents a -80.88%
decrease from the last price of $441.989990234375.
For Vertex Pharmaceuticals Incorporated stock forecast 2031, 12 predictions are offered for each month of 2031 with average Vertex Pharmaceuticals Incorporated stock
forecast of $86.55, a high forecast of $89.69, and a low forecast of $79.84.
The average Vertex Pharmaceuticals Incorporated stock forecast 2031 represents a -80.42%
decrease from the last price of $441.989990234375.
For Vertex Pharmaceuticals Incorporated stock forecast for 2035 (10 year), 6 predictions are offered for each month of 2035 with average Vertex Pharmaceuticals Incorporated stock
forecast of $66.01, a high forecast of $66.36, and a low forecast of $65.57.
The average Vertex Pharmaceuticals Incorporated stock forecast 2035 represents a -85.06%
decrease from the last price of $441.989990234375.
Please, see more forecasts below.
VRTX : Vertex Pharmaceuticals Incorporated stock forecast by Wall Street Analysts
The average Vertex Pharmaceuticals Incorporated stock forecast from last 6 month is $484.95, and this show a -1.14% decrease in average from the prior price target of the each prediction. Also, this average forecast of $484.95 represents a -4.01% decrease from the past average forecast of $505.2, 6 months ago from 35 wall street analysts.
| Date | Firm | previous price target | current price target | current rating |
|---|---|---|---|---|
| 2025-06-17 | RBC Capital | $423.0000 | $420.0000 | Sector Perform |
| 2025-05-06 | JP Morgan | $512.0000 | $515.0000 | Overweight |
| 2025-05-06 | RBC Capital | $420.00 | $423.0000 | Sector Perform |
| 2025-05-06 | Scotiabank | $450.00 | $442.0000 | Sector Perform |
| 2025-05-06 | Morgan Stanley | $462.0000 | $464 | Equal-Weight |
| 2025-05-06 | Cantor Fitzgerald | $535.00 | $535 | Overweight |
| 2025-05-06 | Needham | Hold | ||
| 2025-05-06 | Leerink Partners | $550.0000 | $503.0000 | Market Perform |
| 2025-04-22 | Cantor Fitzgerald | $535.0000 | Overweight | |
| 2025-04-01 | RBC Capital | $408.0000 | $420.0000 | Sector Perform |
| 2025-03-31 | B of A Securities | $555.0000 | $567 | Buy |
| 2025-02-20 | RBC Capital | $407.0000 | $408.0000 | Sector Perform |
| 2025-02-12 | Canaccord Genuity | $408.00 | $424.0000 | Hold |
| 2025-02-11 | Barclays | $435.0000 | $467.0000 | Equal-Weight |
| 2025-02-11 | Cantor Fitzgerald | $480.00 | $480 | Overweight |
| 2025-02-11 | Needham | Hold | ||
| 2025-02-11 | Scotiabank | $433.00 | $450 | Sector Perform |
| 2025-02-11 | RBC Capital | $402.0000 | $407.0000 | Sector Perform |
| 2025-02-11 | Truist Securities | $460.00 | $520 | Buy |
| 2025-02-11 | HC Wainwright & Co. | $550.00 | $550 | Buy |
| 2025-02-11 | Morgan Stanley | $450.0000 | $459 | Equal-Weight |
| 2025-02-11 | UBS | $586.00 | $583 | Buy |
| 2025-02-11 | B of A Securities | $540.0000 | $555 | Buy |
| 2025-02-04 | B of A Securities | $522.00 | $540 | Buy |
| 2025-01-31 | Scotiabank | $430.00 | $433.0000 | Sector Perform |
| 2025-01-31 | Cantor Fitzgerald | $480.0000 | $480 | Overweight |
| 2025-01-31 | HC Wainwright & Co. | $535.0000 | $550.0000 | Buy |
| 2025-01-31 | Needham | Hold | ||
| 2025-01-31 | BMO Capital | $520.00 | $545 | Outperform |
| 2025-01-31 | Barclays | $418.00 | $435 | Equal-Weight |
| 2025-01-30 | Wells Fargo | $460.00 | $460.0000 | Equal-Weight |
| 2025-01-27 | Piper Sandler | $535.00 | $533 | Overweight |
| 2025-01-24 | Cantor Fitzgerald | $480.00 | $480 | Overweight |
| 2025-01-10 | Wells Fargo | $555.00 | $460.0000 | Overweight |
| 2024-12-23 | JP Morgan | $503.00 | $500.0000 | Overweight |
| 2024-12-23 | Scotiabank | $426.0000 | $430.0000 | Sector Perform |
| 2024-12-23 | Truist Securities | $550.00 | $460 | Buy |
| 2024-12-20 | HC Wainwright & Co. | $600.00 | $535.0000 | Buy |
| 2024-12-20 | Needham | Hold | ||
| 2024-12-20 | BMO Capital | $566.0000 | $520 | Outperform |
| 2024-12-20 | Barclays | $509.00 | $418.0000 | Equal-Weight |
| 2024-12-19 | Oppenheimer | Perform | ||
| 2024-12-19 | B of A Securities | $545.0000 | $522 | Buy |
| 2024-12-16 | Stifel | $490.0000 | $494 | Hold |
| 2024-12-09 | Jefferies | $500.0000 | $550.0000 | Buy |
| 2024-11-14 | Citigroup | $575.0000 | Buy | |
| 2024-11-06 | Canaccord Genuity | $361.0000 | $408.0000 | Sell |
| 2024-11-05 | Scotiabank | $480.00 | $486.0000 | Sector Perform |
| 2024-11-05 | UBS | $562.00 | $586.0000 | Buy |
| 2024-11-05 | Cantor Fitzgerald | $480.00 | $480.00 | Overweight |
| 2024-11-05 | RBC Capital | $437.0000 | $451 | Sector Perform |
| 2024-11-05 | JP Morgan | $510.00 | $503.0000 | Overweight |
| 2024-11-05 | Morgan Stanley | $473.0000 | $476 | Equal-Weight |
| 2024-10-30 | Oppenheimer | $550.00 | $540 | Outperform |
| 2024-10-21 | HC Wainwright & Co. | $600.00 | $600.00 | Buy |
| 2024-10-17 | UBS | $477.0000 | $562.0000 | Buy |
| 2024-10-16 | Scotiabank | $480.0000 | Sector Perform | |
| 2024-10-14 | B of A Securities | $550.0000 | $541 | Buy |
| 2024-10-10 | Raymond James | Market Perform | ||
| 2024-10-09 | RBC Capital | $425.00 | $437.0000 | Sector Perform |
| 2024-10-08 | Cantor Fitzgerald | $480.00 | $480.00 | Overweight |
| 2024-10-04 | RBC Capital | $431.00 | $425.0000 | Sector Perform |
| 2024-10-01 | Morgan Stanley | $462.0000 | $474 | Equal-Weight |
| 2024-09-19 | RBC Capital | $431.0000 | $431 | Sector Perform |
| 2024-08-05 | Barclays | $472.00 | $509.0000 | Equal-Weight |
| 2024-08-05 | Truist Securities | $508.00 | $550 | Buy |
| 2024-08-05 | JP Morgan | $505.0000 | $510.0000 | Overweight |
| 2024-08-05 | Oppenheimer | $500.00 | $550 | Outperform |
| 2024-08-05 | HC Wainwright & Co. | $500.00 | $600 | Buy |
| 2024-08-02 | Cantor Fitzgerald | $480.00 | $480.00 | Overweight |
| 2024-08-02 | Guggenheim | $450.0000 | $558 | Buy |
| 2024-08-02 | Piper Sandler | $500.0000 | $535 | Overweight |
| 2024-07-31 | Canaccord Genuity | $371.00 | $376.0000 | Sell |
| 2024-07-26 | Needham | Hold | ||
| 2024-07-23 | TD Cowen | $450.0000 | $500.0000 | Buy |
| 2024-07-22 | Cantor Fitzgerald | $440.00 | $480.0000 | Overweight |
| 2024-07-19 | HC Wainwright & Co. | $462.0000 | $500 | Buy |
| 2024-07-11 | Morgan Stanley | $402.0000 | $455 | Equal-Weight |
| 2024-06-27 | Redburn Atlantic | $545.0000 | Buy | |
| 2024-06-24 | Wells Fargo | $540.00 | $555 | Overweight |
Vertex Pharmaceuticals Incorporated stock forecast for upcoming days
| Date | Price Target | Change |
|---|---|---|
| 2025-06-20 | $426.00 | -3.62% |
| 2025-06-23 | $424.47 | -0.36% |
| 2025-06-24 | $412.28 | -2.87% |
| 2025-06-25 | $401.40 | -2.64% |
| 2025-06-26 | $387.89 | -3.36% |
VRTX : Long term Vertex Pharmaceuticals Incorporated stock forecast for 2025 - 2026 - 2030 - 2035
Forecast for 2025 Jul. is $448.98 , for 2026 Jun. is $386.27 , for 2029 Jun. is $142.88 , for 2030 Jun. is $81.04 , for 2034 Jun. is $68.26 , and for 2035 Jun. is $65.93.
VRTX : Vertex Pharmaceuticals Incorporated stock forecast for 2025
| Date | Price Target | Change |
|---|---|---|
| 2025 Jul. | $448.98 | 1.58% |
| 2025 Aug. | $457.51 | 1.90% |
| 2025 Sep. | $462.89 | 1.17% |
| 2025 Oct. | $464.52 | 0.35% |
| 2025 Nov. | $460.36 | -0.89% |
| 2025 Dec. | $451.63 | -1.90% |
VRTX : Vertex Pharmaceuticals Incorporated stock forecast for 2026
| Date | Price Target | Change |
|---|---|---|
| 2026 Jan. | $440.59 | -2.44% |
| 2026 Feb. | $430.01 | -2.40% |
| 2026 Mar. | $419.50 | -2.44% |
| 2026 Apr. | $408.70 | -2.57% |
| 2026 May. | $397.68 | -2.70% |
| 2026 Jun. | $386.27 | -2.87% |
| 2026 Jul. | $374.04 | -3.16% |
| 2026 Aug. | $359.88 | -3.79% |
| 2026 Sep. | $343.63 | -4.52% |
| 2026 Oct. | $324.13 | -5.67% |
| 2026 Nov. | $302.52 | -6.67% |
| 2026 Dec. | $280.95 | -7.13% |
VRTX : Vertex Pharmaceuticals Incorporated stock forecast for 2027
| Date | Price Target | Change |
|---|---|---|
| 2027 Jan. | $260.68 | -7.21% |
| 2027 Feb. | $243.46 | -6.61% |
| 2027 Mar. | $229.78 | -5.62% |
| 2027 Apr. | $218.63 | -4.85% |
| 2027 May. | $209.65 | -4.11% |
| 2027 Jun. | $201.65 | -3.82% |
| 2027 Jul. | $193.96 | -3.81% |
| 2027 Aug. | $185.94 | -4.14% |
| 2027 Sep. | $177.57 | -4.50% |
| 2027 Oct. | $169.62 | -4.48% |
| 2027 Nov. | $163.15 | -3.81% |
| 2027 Dec. | $158.41 | -2.91% |
VRTX : Vertex Pharmaceuticals Incorporated stock forecast for 2028
| Date | Price Target | Change |
|---|---|---|
| 2028 Jan. | $155.17 | -2.05% |
| 2028 Feb. | $153.59 | -1.02% |
| 2028 Mar. | $153.80 | 0.14% |
| 2028 Apr. | $155.86 | 1.34% |
| 2028 May. | $159.56 | 2.37% |
| 2028 Jun. | $164.29 | 2.97% |
| 2028 Jul. | $169.14 | 2.95% |
| 2028 Aug. | $173.22 | 2.41% |
| 2028 Sep. | $175.78 | 1.48% |
| 2028 Oct. | $176.67 | 0.51% |
| 2028 Nov. | $175.92 | -0.42% |
| 2028 Dec. | $173.70 | -1.26% |
VRTX : Vertex Pharmaceuticals Incorporated stock forecast for 2029
| Date | Price Target | Change |
|---|---|---|
| 2029 Jan. | $170.53 | -1.83% |
| 2029 Feb. | $166.63 | -2.29% |
| 2029 Mar. | $162.03 | -2.76% |
| 2029 Apr. | $156.53 | -3.40% |
| 2029 May. | $150.21 | -4.04% |
| 2029 Jun. | $142.88 | -4.88% |
| 2029 Jul. | $134.91 | -5.58% |
| 2029 Aug. | $126.76 | -6.04% |
| 2029 Sep. | $118.48 | -6.53% |
| 2029 Oct. | $110.40 | -6.82% |
| 2029 Nov. | $102.88 | -6.81% |
| 2029 Dec. | $96.29 | -6.40% |
VRTX : Vertex Pharmaceuticals Incorporated stock forecast for 2030
| Date | Price Target | Change |
|---|---|---|
| 2030 Jan. | $90.91 | -5.60% |
| 2030 Feb. | $86.78 | -4.54% |
| 2030 Mar. | $83.86 | -3.36% |
| 2030 Apr. | $82.04 | -2.18% |
| 2030 May. | $81.15 | -1.08% |
| 2030 Jun. | $81.04 | -0.13% |
| 2030 Jul. | $81.58 | 0.66% |
| 2030 Aug. | $82.61 | 1.26% |
| 2030 Sep. | $83.95 | 1.63% |
| 2030 Oct. | $85.42 | 1.75% |
| 2030 Nov. | $86.84 | 1.66% |
| 2030 Dec. | $88.05 | 1.40% |
VRTX : Vertex Pharmaceuticals Incorporated stock forecast for 2031
| Date | Price Target | Change |
|---|---|---|
| 2031 Jan. | $88.96 | 1.03% |
| 2031 Feb. | $89.51 | 0.61% |
| 2031 Mar. | $89.69 | 0.21% |
| 2031 Apr. | $89.54 | -0.16% |
| 2031 May. | $89.10 | -0.49% |
| 2031 Jun. | $88.40 | -0.79% |
| 2031 Jul. | $87.44 | -1.08% |
| 2031 Aug. | $86.27 | -1.35% |
| 2031 Sep. | $84.88 | -1.61% |
| 2031 Oct. | $83.32 | -1.84% |
| 2031 Nov. | $81.62 | -2.04% |
| 2031 Dec. | $79.84 | -2.18% |
VRTX : Vertex Pharmaceuticals Incorporated stock forecast for 2032
| Date | Price Target | Change |
|---|---|---|
| 2032 Jan. | $78.04 | -2.25% |
| 2032 Feb. | $76.32 | -2.21% |
| 2032 Mar. | $74.76 | -2.05% |
| 2032 Apr. | $73.44 | -1.76% |
| 2032 May. | $72.43 | -1.37% |
| 2032 Jun. | $71.78 | -0.90% |
| 2032 Jul. | $71.50 | -0.40% |
| 2032 Aug. | $71.57 | 0.11% |
| 2032 Sep. | $71.97 | 0.56% |
| 2032 Oct. | $72.61 | 0.89% |
| 2032 Nov. | $73.35 | 1.01% |
| 2032 Dec. | $74.01 | 0.90% |
VRTX : Vertex Pharmaceuticals Incorporated stock forecast for 2033
| Date | Price Target | Change |
|---|---|---|
| 2033 Jan. | $74.43 | 0.56% |
| 2033 Feb. | $74.48 | 0.08% |
| 2033 Mar. | $74.15 | -0.45% |
| 2033 Apr. | $73.47 | -0.92% |
| 2033 May. | $72.53 | -1.28% |
| 2033 Jun. | $71.45 | -1.49% |
| 2033 Jul. | $70.34 | -1.55% |
| 2033 Aug. | $69.31 | -1.46% |
| 2033 Sep. | $68.45 | -1.24% |
| 2033 Oct. | $67.82 | -0.93% |
| 2033 Nov. | $67.42 | -0.58% |
| 2033 Dec. | $67.26 | -0.24% |
VRTX : Vertex Pharmaceuticals Incorporated stock forecast for 2034
| Date | Price Target | Change |
|---|---|---|
| 2034 Jan. | $67.31 | 0.08% |
| 2034 Feb. | $67.53 | 0.33% |
| 2034 Mar. | $67.85 | 0.47% |
| 2034 Apr. | $68.15 | 0.44% |
| 2034 May. | $68.32 | 0.25% |
| 2034 Jun. | $68.26 | -0.08% |
| 2034 Jul. | $67.97 | -0.43% |
| 2034 Aug. | $67.49 | -0.71% |
| 2034 Sep. | $66.91 | -0.87% |
| 2034 Oct. | $66.33 | -0.87% |
| 2034 Nov. | $65.86 | -0.70% |
| 2034 Dec. | $65.60 | -0.40% |
VRTX : Vertex Pharmaceuticals Incorporated stock forecast for 2035
| Date | Price Target | Change |
|---|---|---|
| 2035 Jan. | $65.57 | -0.04% |
| 2035 Feb. | $65.78 | 0.31% |
| 2035 Mar. | $66.11 | 0.50% |
| 2035 Apr. | $66.36 | 0.38% |
| 2035 May. | $66.33 | -0.04% |
| 2035 Jun. | $65.93 | -0.60% |
Financial Data for Vertex Pharmaceuticals Incorporated stock
Frequently Asked Questions about Vertex Pharmaceuticals Incorporated stock forecast
Is Vertex Pharmaceuticals Incorporated a good long term stock?
From Vertex Pharmaceuticals Incorporated stock forecast , Vertex Pharmaceuticals Incorporated (VRTX) stock can be a good investment choice. According to AIPickup, the Vertex Pharmaceuticals Incorporated stock price forecast for 2025 Jul. is $448.9816821287652 From Vertex Pharmaceuticals Incorporated stock forecast , Vertex Pharmaceuticals Incorporated (VRTX) stock cannot be a good investment choice. According to AIPickup, the Vertex Pharmaceuticals Incorporated stock price forecast for 2026 Jun. is $386.265453791693 From Vertex Pharmaceuticals Incorporated stock forecast , Vertex Pharmaceuticals Incorporated (VRTX) stock cannot be a good investment choice. According to AIPickup, the Vertex Pharmaceuticals Incorporated stock price forecast for 2029 Jun. is $142.87960352272148 From Vertex Pharmaceuticals Incorporated stock forecast , Vertex Pharmaceuticals Incorporated (VRTX) stock cannot be a good investment choice. According to AIPickup, the Vertex Pharmaceuticals Incorporated stock price forecast for 2030 Jun. is $81.04300106401455 From Vertex Pharmaceuticals Incorporated stock forecast , Vertex Pharmaceuticals Incorporated (VRTX) stock cannot be a good investment choice. According to AIPickup, the Vertex Pharmaceuticals Incorporated stock price forecast for 2034 Jun. is $68.2644025805372 From Vertex Pharmaceuticals Incorporated stock forecast , Vertex Pharmaceuticals Incorporated (VRTX) stock cannot be a good investment choice. According to AIPickup, the Vertex Pharmaceuticals Incorporated stock price forecast for 2035 Jun. is $65.93126764476087
Is Vertex Pharmaceuticals Incorporated stock overvalued?
Vertex Pharmaceuticals Incorporated (VRTX) stock is expected to go DOWN . Therefore, AIPickup would say that Vertex Pharmaceuticals Incorporated (VRTX) stock is overvalued.
Will Vertex Pharmaceuticals Incorporated stock price go up?
No. The Vertex Pharmaceuticals Incorporated stock price forecast for 2026 Jun. is $386.265453791693
Is Vertex Pharmaceuticals Incorporated stock a good buy now?
Since closing price on 2025-06-17 is $441.989990234375 and forecast for 2026 Jun. is $386.27, Vertex Pharmaceuticals Incorporated stock is not a good 1 year investment.
14 Days Historical Data for Vertex Pharmaceuticals Incorporated stock price
| Date | Close | Open | Low | High |
|---|---|---|---|---|
| VRTX stock price for 2025-05-29 | $447.09 | $444.99 | $442.76 | $449.22 |
| VRTX stock price for 2025-05-30 | $442.05 | $447.64 | $439.37 | $447.99 |
| VRTX stock price for 2025-06-02 | $445.43 | $441.27 | $439.54 | $447.98 |
| VRTX stock price for 2025-06-03 | $446.48 | $444.30 | $439.54 | $449.85 |
| VRTX stock price for 2025-06-04 | $445.85 | $448.04 | $445.84 | $453.87 |
| VRTX stock price for 2025-06-05 | $443.82 | $445.01 | $437.45 | $447.49 |
| VRTX stock price for 2025-06-06 | $450.50 | $443.83 | $443.83 | $451.66 |
| VRTX stock price for 2025-06-09 | $446.15 | $450.78 | $444.84 | $451.52 |
| VRTX stock price for 2025-06-10 | $451.52 | $442.45 | $441.92 | $455.64 |
| VRTX stock price for 2025-06-11 | $452.44 | $451.30 | $450.13 | $460.33 |
| VRTX stock price for 2025-06-12 | $460.06 | $453.19 | $451.94 | $460.06 |
| VRTX stock price for 2025-06-13 | $455.45 | $455.39 | $454.00 | $460.10 |
| VRTX stock price for 2025-06-16 | $450.91 | $456.38 | $448.71 | $457.23 |
| VRTX stock price for 2025-06-17 | $441.99 | $449.43 | $441.21 | $452.71 |